AURKB expression has been linked to therapy related drug resistance in different malignancies including vemurafenib-resistant melanoma [154], temozolomide-resistant glioblastoma [154], and epidermal growth factor receptor tyrosine kinase inhibitor-resistant NSCLC [67]. The gene discussed is AURKB; the disease is glioblastoma.